Healthcare software company Alcidion saw its share price surge 175% in the last financial year, making it one of Cyan Investment Management director Dean Fergie’s favourite share picks.
“This has probably been one of our most successful investments over the past three or four years,” said Dean, the Investment Management Director from Cyan.
Healthcare workers need to make the right decisions. When they’re under pressure, however, mistakes happen. In fact, adverse delivery of healthcare is the third leading cause of death in the US. Alcidion’s hospital decision making and patient tracking software minimises that risk by taking the pressure off busy doctors and nurses.
“We’re using that data to support the decision making process of the clinicians. Not to take the process away, but to relieve the cognitive load on them on their day-to-day delivery of healthcare to patients,” said Alcidion CEO Kate Quirke.
With a healthy net cash balance, huge growth margins of 88%, and being very close to breakeven, Alcidion is in a very strong position as a company.
Importantly, Alcidion has strong recurring revenue channels which are supported by healthcare, being what Kate calls “a very sticky business”. Kate notes that healthcare customers typically stick with a software company for 10 to 20 years.
Alcidion continues to sign on new clients across the UK and Australia including major contracts with the NHS and, most recently, Northern Territory Health.
Reach does not assume responsibility for the accuracy or completeness of any information provided, and the views expressed are not reflective of Reach Markets position.
Any advice contained within this presentation is general advice and does not consider your personal circumstance, you should consider whether it’s appropriate for you.
The information we are giving you is for educational purposes only. “Investing is about understanding your risk” and every time you invest in the share market there is a risk of loss